# LeonaBio, Inc.: financial statements, quarterly

LONA · Nasdaq · CIK 1620463 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/lona.md) · [Financials](/companies/lona/financials.md) · [Filings](/companies/lona/filings.md) · [Insiders](/companies/lona/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/lona/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Research and development | $m | [27.2](/filings/0000950170-24-123372.md) | [23.7 d](/filings/0000950170-25-029069.md) | [21.2](/filings/0000950170-25-068040.md) | [22.2](/filings/0000950170-25-105052.md) | [17.9](/filings/0001193125-25-269544.md) | [9.4 d](/filings/0001193125-26-134565.md) | [4.3](/filings/0001193125-26-211898.md) | [3.7](/filings/0001193125-26-352243.md) | [2.8](/filings/0001193125-25-269544.md) | [6.7 d](/filings/0001193125-26-134565.md) | [11.3](/filings/0001193125-26-211898.md) | [12.7](/filings/0001193125-26-352243.md) |
| Operating income | $m | [(35.0)](/filings/0000950170-24-123372.md) | [(29.0) d](/filings/0000950170-25-029069.md) | [(27.7)](/filings/0000950170-25-068040.md) | [(28.0)](/filings/0000950170-25-105052.md) | [(29.6)](/filings/0001193125-25-269544.md) | [(15.6) d](/filings/0001193125-26-134565.md) | [(9.5)](/filings/0001193125-26-211898.md) | [(7.3)](/filings/0001193125-26-352243.md) | [(6.9)](/filings/0001193125-25-269544.md) | [(78.6) d](/filings/0001193125-26-134565.md) | [(17.2)](/filings/0001193125-26-211898.md) | [(19.5)](/filings/0001193125-26-352243.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net income | $m | [(33.0)](/filings/0000950170-24-123372.md) | [(27.3) d](/filings/0000950170-25-029069.md) | [(26.3)](/filings/0001193125-25-269544.md) | [(26.9)](/filings/0001193125-25-269544.md) | [(28.7)](/filings/0001193125-25-269544.md) | [(15.0) d](/filings/0001193125-26-134565.md) | [(9.1)](/filings/0001193125-26-352243.md) | [(7.0)](/filings/0001193125-26-352243.md) | [(6.6)](/filings/0001193125-25-269544.md) | [(82.9) d](/filings/0001193125-26-134565.md) | [(32.9)](/filings/0001193125-26-352243.md) | [(19.0)](/filings/0001193125-26-352243.md) |
| Diluted EPS | $ per share | [(0.87)](/filings/0000950170-24-123372.md) | not reported | [(0.69)](/filings/0000950170-25-068040.md) | [(0.70)](/filings/0000950170-25-105052.md) | [(7.46)](/filings/0001193125-25-269544.md) | not reported | [(2.34)](/filings/0001193125-26-211898.md) | [(1.78)](/filings/0001193125-26-352243.md) | [(1.68)](/filings/0001193125-25-269544.md) | not reported | [(1.73)](/filings/0001193125-26-211898.md) | [(0.80)](/filings/0001193125-26-352243.md) |
| Basic EPS | $ per share | [(0.87)](/filings/0000950170-24-123372.md) | not reported | [(0.69)](/filings/0000950170-25-068040.md) | [(0.70)](/filings/0000950170-25-105052.md) | [(7.46)](/filings/0001193125-25-269544.md) | not reported | [(2.34)](/filings/0001193125-26-211898.md) | [(1.78)](/filings/0001193125-26-352243.md) | [(1.68)](/filings/0001193125-25-269544.md) | not reported | [(1.73)](/filings/0001193125-26-211898.md) | [(0.80)](/filings/0001193125-26-352243.md) |

- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [110](/filings/0000950170-23-062082.md) | [90.6](/filings/0000950170-25-029069.md) | [77.8](/filings/0000950170-25-068040.md) | [73.8](/filings/0000950170-24-089304.md) | [68.9](/filings/0000950170-24-123372.md) | [48.4](/filings/0001193125-26-134565.md) | [26.4](/filings/0000950170-25-068040.md) | [19.9](/filings/0000950170-25-105052.md) | [20.9](/filings/0001193125-25-269544.md) | [69.3](/filings/0001193125-26-352243.md) | [32.8](/filings/0001193125-26-211898.md) | [32.3](/filings/0001193125-26-352243.md) |
| Current assets | $m | [179](/filings/0000950170-23-062082.md) | [155](/filings/0000950170-25-029069.md) | [129](/filings/0000950170-24-060482.md) | [107](/filings/0000950170-24-089304.md) | [82.0](/filings/0000950170-24-123372.md) | [54.8](/filings/0001193125-26-134565.md) | [39.9](/filings/0000950170-25-068040.md) | [32.2](/filings/0000950170-25-105052.md) | [27.0](/filings/0001193125-25-269544.md) | [89.5](/filings/0001193125-26-352243.md) | [69.2](/filings/0001193125-26-211898.md) | [54.8](/filings/0001193125-26-352243.md) |
| Total assets | $m | [185](/filings/0000950170-23-062082.md) | [160](/filings/0000950170-25-029069.md) | [133](/filings/0000950170-24-060482.md) | [111](/filings/0000950170-24-089304.md) | [86.2](/filings/0000950170-24-123372.md) | [58.8](/filings/0001193125-26-134565.md) | [43.5](/filings/0000950170-25-068040.md) | [35.5](/filings/0000950170-25-105052.md) | [30.0](/filings/0001193125-25-269544.md) | [92.2](/filings/0001193125-26-352243.md) | [71.6](/filings/0001193125-26-211898.md) | [56.9](/filings/0001193125-26-352243.md) |
| Current liabilities | $m | [28.6](/filings/0000950170-23-062082.md) | [28.8](/filings/0000950170-25-029069.md) | [25.6](/filings/0000950170-24-060482.md) | [26.9](/filings/0000950170-24-089304.md) | [27.8](/filings/0000950170-24-123372.md) | [13.1](/filings/0001193125-26-134565.md) | [5.5](/filings/0000950170-25-068040.md) | [3.0](/filings/0000950170-25-105052.md) | [2.8](/filings/0001193125-25-269544.md) | [47.5](/filings/0001193125-26-352243.md) | [6.7](/filings/0001193125-26-211898.md) | [7.8](/filings/0001193125-26-352243.md) |
| Total liabilities | $m | [29.9](/filings/0000950170-23-062082.md) | [30.1](/filings/0000950170-25-029069.md) | [26.7](/filings/0000950170-24-060482.md) | [27.9](/filings/0000950170-24-089304.md) | [28.7](/filings/0000950170-24-123372.md) | [13.9](/filings/0001193125-26-134565.md) | [6.2](/filings/0000950170-25-068040.md) | [3.6](/filings/0000950170-25-105052.md) | [3.2](/filings/0001193125-25-269544.md) | [64.4](/filings/0001193125-26-352243.md) | [22.3](/filings/0001193125-26-211898.md) | [23.3](/filings/0001193125-26-352243.md) |
| Shareholders' equity | $m | [155](/filings/0000950170-24-123372.md) | [130](/filings/0001193125-26-134565.md) | [107](/filings/0001193125-25-269544.md) | [83.3](/filings/0001193125-25-269544.md) | [57.6](/filings/0001193125-25-269544.md) | [44.8](/filings/0001193125-26-352243.md) | [37.3](/filings/0001193125-26-352243.md) | [32.0](/filings/0001193125-26-352243.md) | [26.8](/filings/0001193125-25-269544.md) | [27.8](/filings/0001193125-26-352243.md) | [49.3](/filings/0001193125-26-352243.md) | [33.6](/filings/0001193125-26-352243.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(24.0) d](/filings/0000950170-24-123372.md) | [(26.3) d](/filings/0000950170-25-029069.md) | [(25.8)](/filings/0000950170-25-068040.md) | [(22.3) d](/filings/0000950170-25-105052.md) | [(23.0) d](/filings/0001193125-25-269544.md) | [(26.0) d](/filings/0001193125-26-134565.md) | [(14.7)](/filings/0001193125-26-211898.md) | [(7.0) d](/filings/0001193125-26-352243.md) | [(4.7) d](/filings/0001193125-25-269544.md) | [(19.4) d](/filings/0001193125-26-134565.md) | [(20.9)](/filings/0001193125-26-211898.md) | [(17.0) d](/filings/0001193125-26-352243.md) |
| Capital expenditure | $m | [0.0 d](/filings/0000950170-24-123372.md) | [0.0 d](/filings/0000950170-25-029069.md) | [0.0](/filings/0000950170-25-068040.md) | [0.0 d](/filings/0000950170-25-105052.md) | [0.0 d](/filings/0001193125-25-269544.md) | [0.0 d](/filings/0001193125-26-134565.md) | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [37.8](/filings/0000950170-23-062082.md) | [37.9](/filings/0000950170-24-060482.md) | [38.0](/filings/0000950170-24-089304.md) | [38.1](/filings/0000950170-24-123372.md) | [38.3](/filings/0000950170-25-068040.md) | [38.4](/filings/0000950170-25-105052.md) | [3.9](/filings/0001193125-25-269544.md) | [3.9](/filings/0001193125-26-211898.md) | [3.9](/filings/0001193125-26-352243.md) | [3.9](/filings/0001193125-25-269544.md) | [19.0](/filings/0001193125-26-211898.md) | [23.7](/filings/0001193125-26-352243.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 9,421,663 at 2026-08-04, from the cover of the [10-Q filed 2026-08-14](/filings/0001193125-26-352243.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:44 ET. No prices; not investment advice.